These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 21325938

  • 1. The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast.
    Aviles A, Neri N, Nambo MJ.
    Am J Clin Oncol; 2012 Apr; 35(2):126-9. PubMed ID: 21325938
    [Abstract] [Full Text] [Related]

  • 2. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
    Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ.
    Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
    [Abstract] [Full Text] [Related]

  • 3. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 4. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.
    J Clin Oncol; 2015 Jan 20; 33(3):251-7. PubMed ID: 25135992
    [Abstract] [Full Text] [Related]

  • 5. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.
    Int J Oncol; 2011 Dec 20; 39(6):1413-20. PubMed ID: 21874232
    [Abstract] [Full Text] [Related]

  • 6. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.
    Ann Hematol; 2012 Jun 20; 91(6):837-45. PubMed ID: 22160255
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
    Seker M, Bilici A, Ustaalioglu BO, Yilmaz B, Ozturk B, Ünal A, Dane F, Ozdemir NY, Elkiran ET, Kalender ME, Gumus M, Benekli M.
    Arch Gynecol Obstet; 2011 Aug 20; 284(2):405-9. PubMed ID: 20872226
    [Abstract] [Full Text] [Related]

  • 8. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):569-77. PubMed ID: 23540349
    [Abstract] [Full Text] [Related]

  • 9. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, Salles GA, Berger F, Haioun C, Tilly H, Emile JF, Banham AH, Mounier N, Gisselbrecht C, Feugier P, Coiffier B, Molina TJ.
    J Clin Oncol; 2009 Nov 20; 27(33):5573-9. PubMed ID: 19786664
    [Abstract] [Full Text] [Related]

  • 10. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.
    J Clin Oncol; 2011 Nov 01; 29(31):4079-87. PubMed ID: 21947824
    [Abstract] [Full Text] [Related]

  • 11. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group.
    Ann Hematol; 2006 Apr 01; 85(4):257-62. PubMed ID: 16416337
    [Abstract] [Full Text] [Related]

  • 12. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, Sehn LH, Fu K, Aoun P, Greiner TC, Chan WC, Bierman PJ, Bociek RG, Armitage JO, Vose JM, Gascoyne RD, Weisenburger DD.
    Br J Haematol; 2014 May 01; 165(3):382-91. PubMed ID: 24506200
    [Abstract] [Full Text] [Related]

  • 13. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
    Goto N, Tsurumi H, Kasahara S, Kanemura N, Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, Takemura M, Seishima M, Kito Y, Takami T, Moriwaki H.
    Eur J Haematol; 2011 Sep 01; 87(3):217-27. PubMed ID: 21575062
    [Abstract] [Full Text] [Related]

  • 14. Survival of patients with transformed lymphoma in the rituximab era.
    Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, Zhang L, Buckstein R.
    Ann Hematol; 2014 Jun 01; 93(6):1007-14. PubMed ID: 24414374
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups.
    Br J Haematol; 2008 Feb 01; 140(4):411-9. PubMed ID: 18162120
    [Abstract] [Full Text] [Related]

  • 16. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
    Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkær K, Orazi A, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Møller MB, Young KH, Tzankov A.
    J Clin Pathol; 2013 Nov 01; 66(11):956-61. PubMed ID: 23775435
    [Abstract] [Full Text] [Related]

  • 17. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
    Slack GW, Steidl C, Sehn LH, Gascoyne RD.
    Br J Haematol; 2014 Dec 01; 167(5):608-17. PubMed ID: 25135752
    [Abstract] [Full Text] [Related]

  • 18. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.
    J Clin Oncol; 2011 Apr 10; 29(11):1452-7. PubMed ID: 21383296
    [Abstract] [Full Text] [Related]

  • 19. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ.
    J Clin Oncol; 2006 Jul 01; 24(19):3121-7. PubMed ID: 16754935
    [Abstract] [Full Text] [Related]

  • 20. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
    Sohn BS, Kim SM, Yoon DH, Kim S, Lee DH, Kim JH, Lee SW, Huh J, Suh C.
    Ann Hematol; 2012 Nov 01; 91(11):1731-9. PubMed ID: 22752193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.